Skip to content

Hysteroscopic Morcellator versus Electrosurgical resection for Submucosal Leiomyoma

A Randomised Controlled, Cost Minimisation Trial of Hysteroscopic Morcellation versus Electrosurgical Resection for Submucosal Leiomyomas in Women with Abnormal Uterine Bleeding Type Leiomyoma (AUB-L)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12615000828527
Enrollment
19
Registered
2015-08-11
Start date
2016-07-26
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will compare the use of a mechanical hysteroscopic morcellator to monopolar electrosurgical hysteroscopic resection to remove submucosal fibroid in symptomatic women. We hypothesize the hysteroscopic morcellator may reduce intraoperative time and allow additional procedures to be performed in a single operating list. The primary outcome of this study is to determine the difference if there is a difference in cost between two devices used to to resect the leiomyomas. As the operating time will is the most likely to have an impact on this, the time to resect intrauterine pathology between these two different instruments, from insertion of the hysteroscope to removal of instrumentation will form part of this primary outcome. Secondary outcomes include: Fluid deficit, Completeness of resection, and adverse events This is a prospective, randomised, single blinded study, with a minimum of 162 patients to be enrolled over a 1year recruitment period. All cases must satisfy the inclusion/exclusion criteria and will be followed for 6 months after surgery. Following decision to list a woman for a hysteroscopy and resection of fibroid, women will be considered for the study and offered participation. Women who qualify will be randomised to one of two groups: Hysteroscopic morcellator (Myosure, Registered trademark) with normal saline distension medium or monopolar electrosurgical hysteroscopic resector with a glycine distension medium. To ensure concealment, randomisation of women into treatment groups will occur via phone to an automated randomisation service. At the time of surgery, a diagnostic hysteroscopy will first be performed to confirm requirement for resection of a fibroid. Those that do not require resection will continue to have outcome data collected during the operation and followup but will not be included in analysis. Data collection will occur at: recruitment, on the day of admission for surgery and intraoperatively, postoperative review at 6 weeks after index surgery, and postoperative review at 6 months after index surgery. An economic evaluation will be conducted to determine the relative costs and benefits of hysteroscopic morcellation versus electrosurgical resection.

Interventions

Hysteroscopic morcellator for removal of submucosal leiomyoma A rigid tube 7mm in diameter is introduced into the uterine cavity. It has a light source, camera head, and inflow and outflow valves, and channel to allow the morcellator to be inserted. The hysteroscopic morecellator is a rigid tube with a oscillating blade contained within a metal sheath. It works by sucking material into the open tube and the blade cuts the material and sucks in one movement. The hysteroscopic morcellator to b

Hysteroscopic morcellator for removal of submucosal leiomyoma A rigid tube 7mm in diameter is introduced into the uterine cavity. It has a light source, camera head, and inflow and outflow valves, and channel to allow the morcellator to be inserted. The hysteroscopic morecellator is a rigid tube with a oscillating blade contained within a metal sheath. It works by sucking material into the open tube and the blade cuts the material and sucks in one movement. The hysteroscopic morcellator to be used is the Myosure (Registered trademark) Distension medium is normal saline. The maximum amount allowed to be absorbed by the patient is 2500ml. This will be controlled by aquasence (registered trademark) that will measure the inflow and outflow of normal saline The procedure will be performed by a certified gynaecologist or trainee under their supervision. All gynaecologists involved are experienced in the use of this device. The procedure will be undertaken under general anaesthetic The duration of the procedure will depend on the type, number, and location of leiomyoma. It is expected the average resection time will be 24 minutes.

Sponsors

Gynaecology Research and Clinical Evaluation Group
Lead SponsorOther

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Women undergoing surgical resection of submucosal leiomyoma

Exclusion criteria

1. Pregnant women. 2. Immunocompromised women. 3. Current involvement in any other research project. 4. Women who are suspected to have a gynaecological malignancy

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026